Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial

David W. Dodick, Stewart J. Tepper, Deborah I. Friedman, Amy A. Gelfand, Donald J. Kellerman, Peter C. Schmidt

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Objective: To better understand the utility of using pain freedom and most bothersome headache-associated symptom (MBS) freedom as co-primary endpoints in clinical trials of acute migraine interventions. Background: Adhesive dermally applied microarray (ADAM) is an investigational system for intracutaneous drug administration. The recently completed pivotal Phase 2b/3 study (ZOTRIP), evaluating ADAM zolmitriptan for the treatment of acute moderate to severe migraine, was one of the first large studies to incorporate MBS freedom and pain freedom as co-primary endpoints per recently issued guidance by the US Food and Drug Administration. In this trial, the proportion of patients treated with ADAM zolmitriptan 3.8 mg, who were pain-free and MBS-free at 2 hours post-dose, was significantly higher than for placebo. Methods: We undertook a post-hoc analysis of data from the ZOTRIP trial to examine how the outcomes from this trial compare to what might have been achieved using the conventional co-primary endpoints of pain relief, nausea, photophobia, and phonophobia. Results: Of the 159 patients treated with ADAM zolmitriptan 3.8 mg or placebo, prospectively designated MBS were photophobia (n = 79), phonophobia (n = 43), and nausea (n = 37). Two-hour pain free rates in those with photophobia as the MBS were 36% for ADAM zolmitriptan 3.8 mg and 14% for placebo (P =.02). Corresponding rates for those with phonophobia as the MBS were 14% and 41% (P =.05). For those whose MBS was nausea, corresponding values were 56% and 16%, respectively (P =.01). Two-hour freedom from the MBS for active drug vs placebo were 67% vs 35% (P <.01) for photophobia, 55% vs 43% (P =.45) for phonophobia, and 89% vs 58% for nausea (P =.04). MBS freedom but not pain freedom was achieved in 28%. Only 1 patient (1%) achieved pain freedom, but not MBS freedom. The proportion with both pain and MBS freedom was highest (56%) among those whose MBS was nausea. Conclusion: In this study, the use of MBS was feasible and seemed to compare favorably to the previously required 4 co-primary endpoints.

Original languageEnglish (US)
Pages (from-to)986-992
Number of pages7
JournalHeadache
Volume58
Issue number7
DOIs
StatePublished - Jul 1 2018

Keywords

  • adhesive dermally applied microarray
  • drug delivery
  • headache
  • intracutaneous
  • migraine
  • triptan
  • zolmitriptan

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial'. Together they form a unique fingerprint.

  • Cite this